Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Festuca pratensis pollen, also known as Meadow Fescue grass pollen, is a standardized allergenic extract derived from the pollen of the *Festuca pratensis* plant. It is a biologic product primarily used for both the diagnosis of and immunotherapy for grass pollen allergies. The extract is used in skin tests to confirm sensitivity and in immunotherapy to reduce allergic symptoms like hay fever and rhinitis in patients with confirmed allergies. The mechanism of action involves inducing immune tolerance to grass pollen allergens, thereby reducing IgE-mediated allergic responses. Formulated as a glycerinated solution, it is administered via percutaneous, intradermal, or subcutaneous routes. The product, which received initial U.S. approval in 1997, is manufactured by companies including Greer Laboratories, Inc. and ALK-Abello, Inc., often as a component in standardized grass pollen mixtures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Festuca pratensis pollen.